{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:42:36Z","timestamp":1777585356696,"version":"3.51.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T00:00:00Z","timestamp":1382313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["SpringerPlus"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Compare <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> characteristics and clinical outcomes of brand and generic alendronate.<\/jats:p>\n            <jats:p>Research design and methods: Relevant search terms were input into Medline (\"alendronate\" AND \"generic\" up to August 5, 2013) and any abstracts deemed possibly relevant selected for full paper review and abstraction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Multicentre, randomized, placebo-controlled Phase III clinical trials of substantial size and duration have established the anti-fracture efficacy and safety of brand amino-bisphosphonates. For regulatory approval, generic versions of brand drugs need to demonstrate bioequivalence in young, healthy volunteers and have similar dissolution times. While the potency and amount of active drug within generic formulations must be identical to the brand, differences are permitted in the excipients. Significant differences in tablet disintegration time among different versions of generic and brand alendronate have been reported. Rapidly disintegrating alendronate pills may increase oesophageal bioadhesion and adverse event risk. Oesophageal-bound alendronate or slow disintegrating alendronate tablets may be made inert and ineffective by subsequently ingested food or drink. Investigations have reported a lower persistence to therapy with generic brands of alendronate as compared to brand bisphosphonates and patients switched from brand to generic alendronate have increased adverse event rates and losses in bone mineral density.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Numerous differences exist between brand and generic alendronate including: disintegration time, bioadhesion to the oesophagus, patient persistence to therapy, adverse event incidence, and maintenance of bone mineral density. Generic forms of alendronate warrant closer clinical study before they are ascribed the clinical effectiveness and tolerability of brand alendronate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/2193-1801-2-550","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T19:59:25Z","timestamp":1382385565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A critical review of brand and generic alendronate for the treatment of osteoporosis"],"prefix":"10.1186","volume":"2","author":[{"given":"Jacques P","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth S","family":"Davison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech P","family":"Olszynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,21]]},"reference":[{"issue":"2","key":"1426_CR1","first-page":"84","volume":"56","author":"S Almeida","year":"2006","unstructured":"Almeida S, Almeida A, Filipe A, Penedo C, Rocha A, Lainesse A, et al.: In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulations. Arzneimittelforschung 2006, 56(2):84-89.","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"1426_CR2","first-page":"233","volume":"6","author":"AD Anastasilakis","year":"2007","unstructured":"Anastasilakis AD, Goulis DG, Kita M, Avramidis A: Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Hormones (Athens ) 2007, 6(3):233-241.","journal-title":"Hormones (Athens )"},{"issue":"1","key":"1426_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00198-007-0426-9","volume":"19","author":"L Bessette","year":"2008","unstructured":"Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, et al.: The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008, 19(1):79-86. 10.1007\/s00198-007-0426-9","journal-title":"Osteoporos Int"},{"issue":"9041","key":"1426_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Fracture Intervention Trial Research Group. Lancet 1996, 348(9041):1535-1541. 10.1016\/S0140-6736(96)07088-2","journal-title":"Lancet"},{"issue":"18","key":"1426_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822. 10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"issue":"9","key":"1426_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00198-008-0818-5","volume":"20","author":"J Blouin","year":"2009","unstructured":"Blouin J, Dragomir A, Fredette M, Ste-Marie LG, Fernandes JC, Perreault S: Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int 2009, 20(9):1571-1581. 10.1007\/s00198-008-0818-5","journal-title":"Osteoporos Int"},{"issue":"7","key":"1426_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1185\/030079903125004042","volume":"20","author":"DR Bolanos","year":"2004","unstructured":"Bolanos DR: Comment on Disintegration\/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2004, 20(7):1035-1036.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1426_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al.: Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350(12):1189-1199. 10.1056\/NEJMoa030897","journal-title":"N Engl J Med"},{"issue":"14","key":"1426_CR9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM199610033351412","volume":"335","author":"DO Castell","year":"1996","unstructured":"Castell DO: \"Pill esophagitis\"\u2013the case of alendronate. N Engl J Med 1996, 335(14):1058-1059. 10.1056\/NEJM199610033351412","journal-title":"N Engl J Med"},{"issue":"24","key":"1426_CR10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280(24):2077-2082. 10.1001\/jama.280.24.2077","journal-title":"JAMA"},{"issue":"6","key":"1426_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0016-5107(03)02298-3","volume":"58","author":"Q Dai","year":"2003","unstructured":"Dai Q, Liu JB, Brasseur JG, Thangada VK, Thomas B, Parkman H, et al.: Volume (3-dimensional) space-time reconstruction of esophageal peristaltic contraction by using simultaneous US and manometry. Gastrointest Endosc 2003, 58(6):913-919. 10.1016\/S0016-5107(03)02298-3","journal-title":"Gastrointest Endosc"},{"issue":"4","key":"1426_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1185\/030079908X280725","volume":"24","author":"RJ Dansereau","year":"2008","unstructured":"Dansereau RJ, Crail DJ, Perkins AC: In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Curr Med Res Opin 2008, 24(4):1137-1145. 10.1185\/030079908X280725","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1426_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1185\/03007990802648903","volume":"25","author":"RJ Dansereau","year":"2009","unstructured":"Dansereau RJ, Crail DJ, Perkins AC: In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US. Curr Med Res Opin 2009, 25(2):449-452. 10.1185\/03007990802648903","journal-title":"Curr Med Res Opin"},{"issue":"14","key":"1426_CR14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"PC de Groen","year":"1996","unstructured":"de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al.: Esophagitis associated with the use of alendronate. N Engl J Med 1996, 335(14):1016-1021. 10.1056\/NEJM199610033351403","journal-title":"N Engl J Med"},{"issue":"2","key":"1426_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","volume":"18","author":"JP Devogelaer","year":"1996","unstructured":"Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, et al.: Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996, 18(2):141-150. 10.1016\/8756-3282(95)00436-X","journal-title":"Bone"},{"issue":"3A Suppl","key":"1426_CR16","doi-asserted-by":"publisher","first-page":"23S","DOI":"10.1016\/S0041-1345(99)00109-8","volume":"31","author":"SV Dighe","year":"1999","unstructured":"Dighe SV: A review of the safety of generic drugs. Transplant Proc 1999, 31(3A Suppl):23S-24S.","journal-title":"Transplant Proc"},{"issue":"3","key":"1426_CR17","doi-asserted-by":"publisher","first-page":"G576","DOI":"10.1152\/ajpgi.00014.2002","volume":"283","author":"A Dobrucali","year":"2002","unstructured":"Dobrucali A, Tobey NA, Awayda MS, Argote C, Bdulnour-Nakhoul S, Shao W, et al.: Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am J Physiol Gastrointest Liver Physiol 2002, 283(3):G576-G586.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1426_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0011-393X(02)80010-8","volume":"63","author":"W Drake","year":"2002","unstructured":"Drake W, Worsley D, Lentle BC, Kendler DL: Monitoring oesophageal transit of wax-polished alendronate in healthy postmenopausal women: a new technique for the study of pill transit time. Curr Therp Res 2002, 63: 103-109. 10.1016\/S0011-393X(02)80010-8","journal-title":"Curr Therp Res"},{"issue":"8","key":"1426_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1185\/030079903125002577","volume":"19","author":"S Epstein","year":"2003","unstructured":"Epstein S, Cryer B, Ragi S, Zanchetta JR, Walliser J, Chow J, et al.: Disintegration\/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003, 19(8):781-789. 10.1185\/030079903125002577","journal-title":"Curr Med Res Opin"},{"key":"1426_CR20","first-page":"253","volume":"5","author":"S Epstein","year":"2005","unstructured":"Epstein S, Geusen P, Fisher J, Hill S, Roy S, Rodan G, et al.: Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy. J Appl Res 2005, 5: 253-265.","journal-title":"J Appl Res"},{"issue":"10","key":"1426_CR21","first-page":"1377","volume":"4","author":"B Ettinger","year":"1998","unstructured":"Ettinger B, Pressman A, Schein J: Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998, 4(10):1377-1382.","journal-title":"Am J Manag Care"},{"key":"1426_CR22","volume-title":"Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations","author":"Federal Drug Administration","year":"2003","unstructured":"Federal Drug Administration: Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. 2003. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070124.pdf"},{"key":"1426_CR23","volume-title":"Draft Guidance on Alendronate Sodium","author":"Federal Drug Administration","year":"2008","unstructured":"Federal Drug Administration: Draft Guidance on Alendronate Sodium. 2008. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm082421.pdf"},{"issue":"10","key":"1426_CR24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1359\/jbmr.080510","volume":"23","author":"AM Gallagher","year":"2008","unstructured":"Gallagher AM, Rietbrock S, Olson M, van Staa TP: Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008, 23(10):1569-1575. 10.1359\/jbmr.080510","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1426_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.semarthrit.2005.11.001","volume":"35","author":"L Giangregorio","year":"2006","unstructured":"Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD: Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 2006, 35(5):293-305. 10.1016\/j.semarthrit.2005.11.001","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1426_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/archinte.161.1.107","volume":"161","author":"DY Graham","year":"2001","unstructured":"Graham DY, Malaty HM: Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001, 161(1):107-110. 10.1001\/archinte.161.1.107","journal-title":"Arch Intern Med"},{"key":"1426_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1471-2474-11-68","volume":"11","author":"DT Grima","year":"2010","unstructured":"Grima DT, Papaioannou A, Airia P, Ioannidis G, Adachi JD: Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord 2010, 11: 68. 10.1186\/1471-2474-11-68","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"1426_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1345\/aph.1H218","volume":"41","author":"H Halkin","year":"2007","unstructured":"Halkin H, Dushenat M, Silverman B, Shalev V, Loebstein R, Lomnicky Y, et al.: Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2007, 41(1):29-34.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1426_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00198-007-0471-4","volume":"19","author":"KE Hansen","year":"2008","unstructured":"Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME: Adherence to alendronate in male veterans. Osteoporos Int 2008, 19(3):349-356. 10.1007\/s00198-007-0471-4","journal-title":"Osteoporos Int"},{"issue":"14","key":"1426_CR30","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282(14):1344-1352. 10.1001\/jama.282.14.1344","journal-title":"JAMA"},{"key":"1426_CR31","volume-title":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies","author":"Health Canada","year":"1997","unstructured":"Health Canada: Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies. 1997. http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/applic-demande\/guide-ld\/bio\/gd_cbs_ebc_ld-eng.php"},{"issue":"10","key":"1426_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","volume":"29","author":"M Hiligsmann","year":"2011","unstructured":"Hiligsmann M, Reginster JY: Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 2011, 29(10):895-911. 10.2165\/11539980-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1426_CR33","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","volume":"21","author":"I Imaz","year":"2010","unstructured":"Imaz I, Zegarra P, Gonz\u00e1lez-Enr\u00edquez J, Rubio B, Alcazar R, Amate JM: Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010, 21(11):1943-1951. 10.1007\/s00198-009-1134-4","journal-title":"Osteoporos Int"},{"issue":"5","key":"1426_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1503\/cmaj.081720","volume":"181","author":"G Ioannidis","year":"2009","unstructured":"Ioannidis G, Papaioannou A, Hopman WM, Khtar-Danesh N, Anastassiades T, Pickard L, et al.: Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009, 181(5):265-271. 10.1503\/cmaj.081720","journal-title":"CMAJ"},{"issue":"3","key":"1426_CR35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B Jonsson","year":"2011","unstructured":"Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, et al.: Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011, 22(3):967-982. 10.1007\/s00198-010-1424-x","journal-title":"Osteoporos Int"},{"key":"1426_CR36","first-page":"S216","volume":"10","author":"S Kane","year":"2004","unstructured":"Kane S, Borisov N, Brixner D: Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Manag Care 2004, 10: S216-S228.","journal-title":"Am J Manag Care"},{"issue":"8","key":"1426_CR37","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1185\/03007995.2012.708326","volume":"28","author":"PS Lai","year":"2012","unstructured":"Lai PS, Chua SS, Chong YH, Chan SP: The effect of mandatory generic substitution on the safety of alendronate and patients' adherence. Curr Med Res Opin 2012, 28(8):1347-1355. 10.1185\/03007995.2012.708326","journal-title":"Curr Med Res Opin"},{"issue":"9A","key":"1426_CR38","first-page":"569","volume":"54","author":"A Lainesse","year":"2004","unstructured":"Lainesse A, Ozalp Y, Wong H, Alpan RS: Bioequivalence studies on bisphosphonates: the example of alendronate. Arzneimittelforschung 2004, 54(9A):569-572.","journal-title":"Arzneimittelforschung"},{"issue":"10","key":"1426_CR39","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1002\/jps.21639","volume":"98","author":"G Lamprecht","year":"2009","unstructured":"Lamprecht G: In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition. J Pharm Sci 2009, 98(10):3575-3581. 10.1002\/jps.21639","journal-title":"J Pharm Sci"},{"issue":"4","key":"1426_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.bone.2012.07.009","volume":"51","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Strom O: The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis. Bone 2012, 51(4):637-642. 10.1016\/j.bone.2012.07.009","journal-title":"Bone"},{"issue":"22","key":"1426_CR41","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995, 333(22):1437-1443. 10.1056\/NEJM199511303332201","journal-title":"N Engl J Med"},{"issue":"3","key":"1426_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","volume":"148","author":"C MacLean","year":"2008","unstructured":"MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al.: Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008, 148(3):197-213. 10.7326\/0003-4819-148-3-200802050-00198","journal-title":"Ann Intern Med"},{"issue":"5","key":"1426_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al.: Effect of risedronate on the risk of hip fracture in elderly women, Hip Intervention Program Study Group. N Engl J Med 2001, 344(5):333-340. 10.1056\/NEJM200102013440503","journal-title":"N Engl J Med"},{"issue":"11","key":"1426_CR44","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1016\/S0149-2918(03)80340-5","volume":"25","author":"P Meredith","year":"2003","unstructured":"Meredith P: Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003, 25(11):2875-2890. 10.1016\/S0149-2918(03)80340-5","journal-title":"Clin Ther"},{"issue":"2","key":"1426_CR45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/j.gastro.2004.08.004","volume":"128","author":"RK Mittal","year":"2005","unstructured":"Mittal RK, Liu J, Puckett JL, Bhalla V, Bhargava V, Tipnis N, et al.: Sensory and motor function of the esophagus: lessons from ultrasound imaging. Gastroenterology 2005, 128(2):487-497. 10.1053\/j.gastro.2004.08.004","journal-title":"Gastroenterology"},{"issue":"1","key":"1426_CR46","first-page":"1","volume":"17","author":"National Institutes of Health, USA","year":"2000","unstructured":"National Institutes of Health, USA: Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000, 17(1):1-45.","journal-title":"NIH Consens Statement"},{"issue":"3","key":"1426_CR47","doi-asserted-by":"publisher","first-page":"e32879","DOI":"10.1371\/journal.pone.0032879","volume":"7","author":"S Nayak","year":"2012","unstructured":"Nayak S, Roberts MS, Greenspan SL: Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment. PLoS One 2012, 7(3):e32879. 10.1371\/journal.pone.0032879","journal-title":"PLoS One"},{"issue":"9033","key":"1426_CR48","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(05)64955-0","volume":"348","author":"G Naylor","year":"1996","unstructured":"Naylor G, Davies MH: Oesophageal stricture associated with alendronic acid. Lancet 1996, 348(9033):1030-1031.","journal-title":"Lancet"},{"issue":"5","key":"1426_CR49","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00198-008-0743-7","volume":"20","author":"A Papaioannou","year":"2008","unstructured":"Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L, et al.: The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2008, 20(5):703-714.","journal-title":"Osteoporos Int"},{"issue":"17","key":"1426_CR50","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al.: 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010, 182(17):1864-1873. 10.1503\/cmaj.100771","journal-title":"CMAJ"},{"issue":"5","key":"1426_CR51","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D: Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US. Appl Health Econ Health Policy 2013, 11(5):485-97. 10.1007\/s40258-013-0047-8","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"1426_CR52","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.clinthera.2008.04.018","volume":"30","author":"AC Perkins","year":"2008","unstructured":"Perkins AC, Blackshaw PE, Hay PD, Lawes SC, Atherton CT, Dansereau RJ, et al.: Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther 2008, 30(5):834-844. 10.1016\/j.clinthera.2008.04.018","journal-title":"Clin Ther"},{"issue":"5","key":"1426_CR53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"AG Porras","year":"1999","unstructured":"Porras AG, Holland SD, Gertz BJ: Pharmacokinetics of alendronate. Clin Pharmacokinet 1999, 36(5):315-328. 10.2165\/00003088-199936050-00002","journal-title":"Clin Pharmacokinet"},{"key":"1426_CR54","volume-title":"Fosamax (alendronate sodium) tablets and oral solution","author":"Prescribing information","year":"2010","unstructured":"Prescribing information: Fosamax (alendronate sodium) tablets and oral solution. Whitehouse Station, NJ: Merck & Co., Inc; 2010. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/f\/fosamax\/fosamax_pi.pdf"},{"issue":"6","key":"1426_CR55","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","volume":"19","author":"V Rabenda","year":"2008","unstructured":"Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al.: Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008, 19(6):811-818. 10.1007\/s00198-007-0506-x","journal-title":"Osteoporos Int"},{"issue":"4","key":"1426_CR56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00223-010-9401-0","volume":"87","author":"SH Ralston","year":"2010","unstructured":"Ralston SH, Kou TD, Wick-Urban B, Steinbuch M, Masud T: Risk of upper gastrointestinal tract events in risedronate users switched to alendronate. Calcif Tissue Int 2010, 87(4):298-304. 10.1007\/s00223-010-9401-0","journal-title":"Calcif Tissue Int"},{"key":"1426_CR57","volume-title":"Search Tool for Statistical Information (STSI)","author":"R\u00e9gie de l'assurance maladie du Qu\u00e9bec","year":"2010","unstructured":"R\u00e9gie de l'assurance maladie du Qu\u00e9bec: Search Tool for Statistical Information (STSI). 2010. https:\/\/www.prod.ramq.gouv.qc.ca\/IST\/CD\/CDF_DifsnInfoStats\/CDF1_CnsulInfoStatsCNC_iut\/DifsnInfoStats.aspx?ETAPE_COUR=2%26;LANGUE=en-CA"},{"issue":"2","key":"1426_CR58","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/mol.59.2.193","volume":"59","author":"AA Reszka","year":"2001","unstructured":"Reszka AA, Halasy-Nagy J, Rodan GA: Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001, 59(2):193-202.","journal-title":"Mol Pharmacol"},{"issue":"5","key":"1426_CR59","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.clinthera.2009.05.001","volume":"31","author":"SY Rhim","year":"2009","unstructured":"Rhim SY, Park JH, Park YS, Lee MH, Kim DS, Shaw LM, et al.: Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. Clin Ther 2009, 31(5):1037-1045. 10.1016\/j.clinthera.2009.05.001","journal-title":"Clin Ther"},{"issue":"2","key":"1426_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00296-009-0940-5","volume":"30","author":"JD Ringe","year":"2009","unstructured":"Ringe JD, Moller G: Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009, 30(2):213-221. 10.1007\/s00296-009-0940-5","journal-title":"Rheumatol Int"},{"issue":"11","key":"1426_CR61","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","volume":"17","author":"R Rizzoli","year":"2002","unstructured":"Rizzoli R, Greenspan SL, Bone G III, Schnitzer TJ, Watts NB, Adami S, et al.: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002, 17(11):1988-1996. 10.1359\/jbmr.2002.17.11.1988","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1426_CR62","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","volume":"17","author":"M Rossini","year":"2006","unstructured":"Rossini M, Bianchi G, Di MO, Giannini S, Minisola S, Sinigaglia L, et al.: Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006, 17(6):914-921. 10.1007\/s00198-006-0073-6","journal-title":"Osteoporos Int"},{"issue":"1","key":"1426_CR63","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano ) 2000, 12(1):1-12.","journal-title":"Alendronate Once-Weekly Study Group. Aging (Milano )"},{"issue":"5","key":"1426_CR64","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ejps.2007.03.012","volume":"31","author":"M Shakweh","year":"2007","unstructured":"Shakweh M, Bravo-Osuna I, Ponchel G: Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. Eur J Pharm Sci 2007, 31(5):262-270. 10.1016\/j.ejps.2007.03.012","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"1426_CR65","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00198-008-0795-8","volume":"20","author":"O Sheehy","year":"2009","unstructured":"Sheehy O, Kindundu CM, Barbeau M, LeLorier J: Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 2009, 20(8):1369-1376. 10.1007\/s00198-008-0795-8","journal-title":"Osteoporos Int"},{"issue":"9","key":"1426_CR66","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00198-008-0829-2","volume":"20","author":"O Sheehy","year":"2009","unstructured":"Sheehy O, Kindundu C, Barbeau M, LeLorier J: Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int 2009, 20(9):1583-1594. 10.1007\/s00198-008-0829-2","journal-title":"Osteoporos Int"},{"issue":"8","key":"1426_CR67","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81(8):1013-1022. 10.4065\/81.8.1013","journal-title":"Mayo Clin Proc"},{"issue":"2 Suppl","key":"1426_CR68","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL: Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009, 122(2 Suppl):S3-S13.","journal-title":"Am J Med"},{"issue":"9","key":"1426_CR69","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","volume":"30","author":"W Strampel","year":"2007","unstructured":"Strampel W, Emkey R, Civitelli R: Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007, 30(9):755-763. 10.2165\/00002018-200730090-00003","journal-title":"Drug Saf"},{"issue":"8","key":"1426_CR70","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00198-011-1850-4","volume":"23","author":"O Strom","year":"2012","unstructured":"Strom O, Landfeldt E: The association between automatic generic substitution and treatment persistence with oral bisphosphonates. Osteoporos Int 2012, 23(8):2201-2209. 10.1007\/s00198-011-1850-4","journal-title":"Osteoporos Int"},{"issue":"4","key":"1426_CR71","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00198-012-2115-6","volume":"24","author":"O Strom","year":"2013","unstructured":"Strom O, Jonsson B, Kanis JA: Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis. Osteoporos Int 2013, 24(4):1491-1502. 10.1007\/s00198-012-2115-6","journal-title":"Osteoporos Int"},{"issue":"8","key":"1426_CR72","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/jbmr.1615","volume":"27","author":"JE Tarride","year":"2012","unstructured":"Tarride JE, Guo N, Hopkins R, Leslie WD, Morin S, Adachi JD, et al.: The burden of illness of osteoporosis in Canadian men. J Bone Miner Res 2012, 27(8):1830-1838. 10.1002\/jbmr.1615","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1426_CR73","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1210\/jc.85.9.3109","volume":"85","author":"RP Tonino","year":"2000","unstructured":"Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, et al.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women, Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85(9):3109-3115. 10.1210\/jc.85.9.3109","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1426_CR74","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00774-013-0440-2","volume":"31","author":"JF van Boven","year":"2013","unstructured":"van Boven JF, de Boer PT, Postma MJ, Vegter S: Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 2013, 31(5):562-70. 10.1007\/s00774-013-0440-2","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"1426_CR75","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00198-006-0230-y","volume":"18","author":"D Weycker","year":"2007","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G: Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007, 18(3):271-277. 10.1007\/s00198-006-0230-y","journal-title":"Osteoporos Int"},{"key":"1426_CR76","volume-title":"Mulit-source pharmaceutical products: WHO guideline on registration requirements to establish interchangeability. TRS 863","author":"World Health Organization","year":"1996","unstructured":"World Health Organization: Mulit-source pharmaceutical products: WHO guideline on registration requirements to establish interchangeability. TRS 863. Geneva, Switzerland: WHO. WHO Technical Support Series; 1996."},{"issue":"4","key":"1426_CR77","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/BF02968579","volume":"29","author":"MH Yun","year":"2006","unstructured":"Yun MH, Woo JS, Kwon KI: Bioequivalence and pharmacokinetics of 70 mg alendronate sodium tablets by measuring alendronate in plasma. Arch Pharm Res 2006, 29(4):328-332. 10.1007\/BF02968579","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1426_CR78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/pds.3361","volume":"22","author":"H Yun","year":"2013","unstructured":"Yun H, Curtis JR, Saag K, Kilgore M, Muntner P, Smith W, et al.: Generic alendronate use among Medicare beneficiaries: are Part D data complete? Pharmacoepidemiol Drug Saf 2013, 22(1):55-63. 10.1002\/pds.3361","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["SpringerPlus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2193-1801-2-550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2193-1801-2-550\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2193-1801-2-550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2193-1801-2-550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:01:50Z","timestamp":1630569710000},"score":1,"resource":{"primary":{"URL":"https:\/\/springerplus.springeropen.com\/articles\/10.1186\/2193-1801-2-550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,21]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1186\/2193-1801-2-550","relation":{},"ISSN":["2193-1801"],"issn-type":[{"value":"2193-1801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,21]]},"assertion":[{"value":"11 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"550"}}